## Michael T Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5425300/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nature Communications, 2022, 13, 245.	5.8	17
2	Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX). Methods in Molecular Biology, 2022, 2471, 195-207.	0.4	0
3	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. Cancer Research, 2022, 82, P5-07-01-P5-07-01.	0.4	0
4	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer, 2022, 3, 232-250.	5.7	133
5	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	1.6	7
6	Abstract PR009: Investigating dynamics of the mitochondrial network in triple negative breast cancer chemotherapy resistance. Cancer Research, 2022, 82, PR009-PR009.	0.4	0
7	PHGDH heterogeneity potentiates cancerÂcell dissemination and metastasis. Nature, 2022, 605, 747-753.	13.7	77
8	In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts. Journal of Mammary Gland Biology and Neoplasia, 2022, 27, 211-230.	1.0	5
9	Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma. Analytical Chemistry, 2022, 94, 9540-9547.	3.2	11
10	VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk. Oncogene, 2021, 40, 964-979.	2.6	50
11	Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell, 2021, 184, 384-403.e21.	13.5	94
12	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
13	Abstract 3009: A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. , 2021, , .		0
14	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
15	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	5.8	58
16	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Research, 2021, 81, 6259-6272.	0.4	10
17	Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics. Cancer Research Communications, 2021, 1, 178-193.	0.7	8
18	Hoxd10 Is Required Systemically for Secretory Activation in Lactation and Interacts Genetically with Hoxd9. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 145-162.	1.0	1

#	Article	IF	CITATIONS
19	Landscape analysis of adjacent gene rearrangements reveals BCL2L14–ETV6 gene fusions in more aggressive triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9912-9921.	3.3	17
20	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight, 2020, 5, .	2.3	22
21	Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine. Tomography, 2020, 6, 273-287.	0.8	11
22	Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer. Journal of Visualized Experiments, 2020, , .	0.2	8
23	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular Cancer Research, 2019, 17, 2063-2076.	1.5	20
24	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. Journal of Clinical Medicine, 2019, 8, 1772.	1.0	36
25	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
26	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer, 2019, 19, 220.	1.1	19
27	Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Research, 2019, 79, 61-71.	0.4	33
28	C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes. Oncogene, 2019, 38, 3765-3780.	2.6	50
29	S100a4-Cre–mediated deletion of Ptch1 causes hypogonadotropic hypogonadism: role of pituitary hematopoietic cells in endocrine regulation. JCl Insight, 2019, 4, .	2.3	7
30	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature Medicine, 2018, 24, 505-511.	15.2	47
31	TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 489-500.	0.4	122
32	Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. Journal of Clinical Investigation, 2018, 128, 1283-1299.	3.9	163
33	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nature Communications, 2018, 9, 3815.	5.8	137
34	gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. Molecular and Cellular Proteomics, 2018, 17, 2270-2283.	2.5	71
35	Epithelial and non-epithelial <i>Patched-1 (Ptch1)</i> play opposing roles to regulate proliferation and morphogenesis of the mouse mammary gland. Development (Cambridge), 2017, 144, 1317-1327.	1.2	9
36	Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomaterialia, 2017, 58, 466-478.	4.1	41

#	Article	IF	CITATIONS
37	New paradigms for the Hedgehog signaling network in mammary gland development and breast Cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 315-332.	3.3	34
38	EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications, 2017, 8, 15773.	5.8	126
39	Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature, 2017, 544, 250-254.	13.7	555
40	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.4	92
41	The Terminal End Bud: the Little Engine that Could. Journal of Mammary Gland Biology and Neoplasia, 2017, 22, 93-108.	1.0	137
42	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	2.7	189
43	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature Cell Biology, 2016, 18, 632-644.	4.6	174
44	Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Reports, 2016, 14, 2154-2165.	2.9	232
45	The Pursuit of Truth in the Company of Friends. Journal of Mammary Gland Biology and Neoplasia, 2016, 21, 77-79.	1.0	0
46	A Geometrically-Constrained Mathematical Model of Mammary Gland Ductal Elongation Reveals Novel Cellular Dynamics within the Terminal End Bud. PLoS Computational Biology, 2016, 12, e1004839.	1.5	47
47	Ubr3, a Novel Modulator of Hh Signaling Affects the Degradation of Costal-2 and Kif7 through Poly-ubiquitination. PLoS Genetics, 2016, 12, e1006054.	1.5	17
48	Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Research, 2015, 17, 17.	2.2	225
49	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Research, 2015, 17, 3.	2.2	48
50	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Reports, 2015, 12, 511-524.	2.9	39
51	An essential role for Cα <sub>i2</sub> in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Science Signaling, 2015, 8, ra92.	1.6	17
52	Identifying and targeting tumor-initiating cells in the treatment of breast cancer. Endocrine-Related Cancer, 2015, 22, R135-R155.	1.6	42
53	Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy. Journal of Biomolecular Screening, 2014, 19, 878-889.	2.6	31
54	Wnt-Responsive Cancer Stem Cells Are Located Close to Distorted Blood Vessels and Not in Hypoxic Regions in a p53-Null Mouse Model of Human Breast Cancer. Stem Cells Translational Medicine, 2014, 3, 857-866.	1.6	8

#	Article	IF	CITATIONS
55	STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer. Stem Cells, 2014, 32, 2571-2582.	1.4	91
56	Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6991-6996.	3.3	69
57	Establishment of Patientâ€Derived Xenograft (PDX) Models of Human Breast Cancer. Current Protocols in Mouse Biology, 2013, 3, 21-29.	1.2	34
58	Separation by Cell Size Enriches for Mammary Stem Cell Repopulation Activity. Stem Cells Translational Medicine, 2013, 2, 199-203.	1.6	16
59	Three-dimensional vasculature reconstruction of tumour microenvironment via local clustering and classification. Interface Focus, 2013, 3, 20130015.	1.5	7
60	Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research, 2013, 19, 1512-1524.	3.2	224
61	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.4	394
62	Abstract IA09: Targeting tumor-initiating cells in xenograft models of human breast cancer. , 2013, , .		0
63	Estrogen Promotes ER-Negative Tumor Growth and Angiogenesis through Mobilization of Bone Marrow–Derived Monocytes. Cancer Research, 2012, 72, 2705-2713.	0.4	51
64	A Mystery Wrapped in an Enigma: Matrigel Enhancement of Mammary Cell Growth and Morphogenesis. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 99-101.	1.0	9
65	Integrative physical oncology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2012, 4, 1-14.	6.6	29
66	Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials, 2012, 33, 1455-1461.	5.7	91
67	Coupling Oriented Hidden Markov Random Field Model with Local Clustering for Segmenting Blood Vessels and Measuring Spatial Structures in Images of Tumor Microenvironment. , 2011, , .		4
68	Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened. Developmental Biology, 2011, 352, 116-127.	0.9	36
69	P190A RhoGAP is required for mammary gland development. Developmental Biology, 2011, 360, 1-10.	0.9	18
70	Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. Journal of Theoretical Biology, 2011, 269, 138-149.	0.8	36
71	High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy. Clinical Cancer Research, 2011, 17, 2314-2327.	3.2	112
72	Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells. Clinical Cancer Research, 2011, 17, 6510-6521.	3.2	47

#	Article	IF	CITATIONS
73	Hedgehog Signaling in Mammary Gland Development and Breast Cancer. , 2011, , 131-149.		0
74	Hedgehog Signaling in the Normal and Neoplastic Mammary Gland. Current Drug Targets, 2010, 11, 1103-1111.	1.0	23
75	Decreased TGFÎ <sup>2</sup> signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment, 2010, 119, 305-314.	1.1	56
76	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment, 2010, 121, 1-11.	1.1	169
77	Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells. PLoS ONE, 2010, 5, e12180.	1.1	148
78	Constitutive Activation of Smoothened Leads to Female Infertility and Altered Uterine Differentiation in the Mouse1. Biology of Reproduction, 2010, 82, 991-999.	1.2	47
79	Activation of Erk by sonic hedgehog independent of canonical hedgehog signalling. International Journal of Biochemistry and Cell Biology, 2010, 42, 1462-1471.	1.2	52
80	Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. Journal of Cell Biology, 2009, 185, 811-826.	2.3	113
81	<i>Ptch1</i> is required locally for mammary gland morphogenesis and systemically for ductal elongation. Development (Cambridge), 2009, 136, 1423-1432.	1.2	32
82	Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Research and Treatment, 2009, 115, 505-521.	1.1	95
83	Tumor-Initiating Cells and Treatment Resistance: How Goes the War?. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 1-2.	1.0	3
84	Methods for Preparing Fluorescent and Neutral Red-Stained Whole Mounts of Mouse Mammary Glands. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 411-415.	1.0	17
85	Methods in Mammary Gland Biology and Breast Cancer Research: An Update. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 365-365.	1.0	6
86	Response to the Letter by Smith et al Stem Cells, 2009, 27, 1224-1225.	1.4	1
87	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	3.3	1,257
88	Evidence That an Early Pregnancy Causes a Persistent Decrease in the Number of Functional Mammary Epithelial Stem Cells—Implications for Pregnancy-Induced Protection Against Breast Cancer. Stem Cells, 2008, 26, 3205-3209.	1.4	60
89	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute, 2008, 100, 672-679.	3.0	1,632
90	Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-ήB and Snail. Molecular and Cellular Biology, 2007, 27, 3165-3175.	1.1	219

#	Article	IF	CITATIONS
91	Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (Cambridge), 2007, 134, 1231-1242.	1.2	161
92	Milking Biological Diversity For All It's Worth—What Do Other Model Systems Teach Us About Mammary Gland Development and Function?. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 183-185.	1.0	0
93	Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17396-17401.	3.3	101
94	Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 1169-1177.	0.8	189
95	Embryogenesis and Oncogenesis: Dr Jekyll and Mr Hyde. Journal of Mammary Gland Biology and Neoplasia, 2004, 9, 105-107.	1.0	2
96	Next Stop, the Twilight Zone: Hedgehog Network Regulation of Mammary Gland Development. Journal of Mammary Gland Biology and Neoplasia, 2004, 9, 165-181.	1.0	63
97	The Cli2 Transcription Factor Is Required for Normal Mouse Mammary Gland Development. Developmental Biology, 2001, 238, 133-144.	0.9	91
98	Hedgehog signaling in mouse mammary gland development and neoplasia. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 53-66.	1.0	44
99	Homeobox genes in mammary gland development and neoplasia. Breast Cancer Research, 2000, 2, 158-69.	2.2	70
100	Regulated expression patterns of IRX-2 , an Iroquois-class homeobox gene, in the human breast. Cell and Tissue Research, 1999, 296, 549-554.	1.5	25